Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.52 |
| ▸ | MAPT | P10636 | 10/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | HTR2B | P41595 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.44 |
| ▸ | LMNA | P02545 | 4/20 | 0.44 |
| ▸ | FES | P07332 | 1/20 | 0.43 |
| ▸ | FER | P16591 | 1/20 | 0.43 |
| ▸ | TYK2 | P29597 | 1/20 | 0.43 |
| ▸ | FRK | P42685 | 1/20 | 0.43 |
| ▸ | SYK | P43405 | 1/20 | 0.43 |
| ▸ | CAMK1D | Q8IU85 | 1/20 | 0.43 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL430027 | 1.00 | SIGMAR1 (0.52) | SIGMAR1MAPTALDH1A1KMT2AL3MBTL1 | |
| SCHEMBL428539 | 0.91 | KDM4E (0.54) | SIGMAR1MAPTALDH1A1KMT2AL3MBTL1 | |
| SCHEMBL428538 | 0.91 | KDM4E (0.54) | SIGMAR1MAPTALDH1A1KMT2AL3MBTL1 | |
| SCHEMBL428535 | 0.88 | MAPT (0.52) | MAPTALDH1A1KMT2AL3MBTL1NPC1 | |
| SCHEMBL428536 | 0.88 | MAPT (0.52) | MAPTALDH1A1KMT2AL3MBTL1NPC1 | |
| SCHEMBL424050 | 0.87 | MAPT (0.44) | SIGMAR1MAPTALDH1A1KMT2AL3MBTL1 | |
| SCHEMBL424769 | 0.87 | MAPT (0.44) | MAPTALDH1A1KMT2AL3MBTL1NPC1 | |
| SCHEMBL429021 | 0.87 | MAPT (0.47) | MAPTALDH1A1KMT2AL3MBTL1NPC1 | |
| SCHEMBL424770 | 0.87 | MAPT (0.44) | MAPTALDH1A1KMT2AL3MBTL1NPC1 | |
| SCHEMBL429022 | 0.87 | MAPT (0.47) | MAPTALDH1A1KMT2AL3MBTL1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8173651-B2 | Pyridine compounds | SYNTA PHARMACEUTICALS CORPORATION (US) | 2012-05-08 | — | — | US | claimed |
| US-7687498-B2 | Pyridine compounds | SYNTA PHARMACEUTICALS CORPORATION (US) | 2010-03-30 | — | — | US | claimed |
| US-7338951-B2 | Pyridine compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2008-03-04 | — | — | US | claimed |
| US-20050250774-A1 | Pyridine compounds | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2005-11-10 | — | — | US | claimed |
| US-20150174132-A1 | METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS | SYNTA PHARMACEUTICALS CORP (US) | 2015-06-25 | — | — | US | disclosed |
| US-8173651-B2 | Pyridine compounds | SYNTA PHARMACEUTICALS CORPORATION (US) | 2012-05-08 | — | — | US | disclosed |
| US-20120021434-A1 | METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS | SYNTA PHARMACEUTICALS CORP. (US) | 2012-01-26 | — | — | US | disclosed |
| US-20110098267-A1 | TOPICAL FORMULATIONS FOR THE TREATMENT OF PSORIASIS | SYNTA PHARMACEUTICALS CORPORATION (US) | 2011-04-28 | — | — | US | disclosed |
| US-20100173413-A1 | PYRIDINE COMPOUNDS | SYNTA PHARMACEUTICALS CORPORATION (US) | 2010-07-08 | — | — | US | disclosed |
| US-7687498-B2 | Pyridine compounds | SYNTA PHARMACEUTICALS CORPORATION (US) | 2010-03-30 | — | — | US | disclosed |
| US-20090163708-A1 | PROCESS FOR PREPARING MESYLATE SALTS OF IL-12 INHIBITORY COMPOUNDS | SYNTA PHARMACEUTICALS CORP. (US) | 2009-06-25 | — | — | US | disclosed |
| US-20080167300-A1 | PYRIDINE COMPOUNDS | MADRIGAL PHARMACEUTICALS, INC. | 2008-07-10 | — | — | US | disclosed |
| US-20070032493-A1 | Method for treating B cell regulated autoimmune disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167300-A1 | PYRIDINE COMPOUNDS | IL2, IL4, IL6 | SIGMAR1 3553/4885MAPT 1165/4885ALDH1A1 334/4885 |
| US-20110098267-A1 | TOPICAL FORMULATIONS FOR THE TREATMENT OF PSORIASIS | IL17A, IL23R, IL15 | SIGMAR1 4309/4885MAPT 238/4885ALDH1A1 1903/4885 |
| US-20150174132-A1 | METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS | REL, NFATC1, BCL6 | SIGMAR1 3961/4885MAPT 4316/4885ALDH1A1 3468/4885 |
| US-20100173413-A1 | PYRIDINE COMPOUNDS | IL2, IL4, IL6 | SIGMAR1 3553/4885MAPT 1165/4885ALDH1A1 334/4885 |
| US-20050250774-A1 | Pyridine compounds | IL2, IL4, IL6 | SIGMAR1 3553/4885MAPT 1165/4885ALDH1A1 334/4885 |
| US-20090163708-A1 | PROCESS FOR PREPARING MESYLATE SALTS OF IL-12 INHIBITORY COMPOUNDS | IL17A, IL23R, IL2 | SIGMAR1 4405/4885MAPT 2815/4885ALDH1A1 747/4885 |
| US-20070032493-A1 | Method for treating B cell regulated autoimmune disorders | REL, NFATC1, BCL6 | SIGMAR1 3961/4885MAPT 4316/4885ALDH1A1 3468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.